LORAZEPAM TABLET
Land: Canada
Språk: engelsk
Kilde: Health Canada
Preparatomtale
(SPC)
26-08-2014
Noen dokumenter for dette produktet er ikke tilgjengelig for øyeblikket, du kan sende en forespørsel til kundeservicen vår, og vi vil varsle deg så snart vi kan få dem.
Send forespørsel.
Send forespørsel.
Aktiv ingrediens:
LORAZEPAM
Tilgjengelig fra:
SIVEM PHARMACEUTICALS ULC
ATC-kode:
N05BA06
INN (International Name):
LORAZEPAM
Dosering :
0.5MG
Legemiddelform:
TABLET
Sammensetning:
LORAZEPAM 0.5MG
Administreringsrute:
ORAL
Enheter i pakken:
100/500
Resept typen:
Targeted (CDSA IV)
Terapeutisk område:
BENZODIAZEPINES
Produkt oppsummering:
Active ingredient group (AIG) number: 0110731003; AHFS:
Autorisasjon status:
CANCELLED PRE MARKET
Autorisasjon dato:
2018-07-03
Preparatomtale
PRODUCT MONOGRAPH
LORAZEPAM
LORAZEPAM TABLETS USP
0.5 MG, 1 MG AND 2 MG
ANXIOLYTIC-SEDATIVE
SIVEM PHARMACEUTICALS ULC
4705 DOBRIN STREET
SAINT-LAURENT, QUÉBEC
H4R 2P7
DATE OF PREPARATION: AUGUST 20, 2014
CONTROL NO. : 176952
Lorazepam Product Monograph
Page 2 of 24
TABLE OF CONTENTS
PRESCRIBING INFORMATION
.............................................................................................
1
ACTIONS AND CLINICAL PHARMACOLOGY
.......................................................................
3
INDICATIONS AND CLINICAL USE
.......................................................................................
6
CONTRAINDICATIONS
..........................................................................................................
6
WARNINGS
...........................................................................................................................
6
PRECAUTIONS
......................................................................................................................
7
DRUG INTERACTIONS
..........................................................................................................
9
ADVERSE REACTIONS
.......................................................................................................
10
SYMPTOMS AND TREATMENT OF OVERDOSE
............................................................... 11
DOSAGE AND ADMINISTRATION
.......................................................................................
11
AVAILABILITY OF DOSAGE FORMS
..................................................................................
12
PHARMACEUTICAL INFORMATION
...................................................................................
13
PHARMACOLOGY................................................................................................................
14
TOXICOLOGY.......................................................................................................................
16
REFERENCES
.................................................
Les hele dokumentet
